HMGN (Hemagen Diagnostics) Ending Cash Position: $0.07 Mil (As of Sep. 2012)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Hemagen Diagnostics Ending Cash Position?

Hemagen Diagnostics HMGN Ending Cash Position is $0.07 Mil as of Sep. 2012.

Hemagen Diagnostics's Ending Cash Position for the quarter that ended in Sep. 2012 was $0.07 Mil.

Hemagen Diagnostics's quarterly Ending Cash Position increased from Mar. 2012 ($0.09 Mil) to Jun. 2012 ($0.11 Mil) but then declined from Jun. 2012 ($0.11 Mil) to Sep. 2012 ($0.07 Mil).

Hemagen Diagnostics's annual Ending Cash Position increased from Sep. 2010 ($0.15 Mil) to Sep. 2011 ($0.21 Mil) but then declined from Sep. 2011 ($0.21 Mil) to Sep. 2012 ($0.07 Mil).

Hemagen Diagnostics Ending Cash Position Related Terms

Hemagen Diagnostics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Hemagen Diagnostics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemagen Diagnostics Ending Cash Position Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.16 0.15 0.21 0.07

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.02 0.09 0.11 0.07

Hemagen Diagnostics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Hemagen Diagnostics's Ending Cash Position for the fiscal year that ended in Sep. 2012 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.214+-0.148
=0.07

Hemagen Diagnostics's Ending Cash Position for the quarter that ended in Sep. 2012 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.108+-0.042
=0.07

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.07 Mil mean?
Hemagen Diagnostics (HMGN) has a Ending Cash Position of $0.07 Mil as of Sep. 2012. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Hemagen Diagnostics and its competitors.
Is Hemagen Diagnostics' Ending Cash Position too high?
Hemagen Diagnostics' current Ending Cash Position is $0.07 Mil.
How does Hemagen Diagnostics' Ending Cash Position compare to OBMP and NSPX?
Hemagen Diagnostics' Ending Cash Position of $0.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Hemagen Diagnostics and its competitors. Hemagen Diagnostics's current Ending Cash Position is $0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemagen Diagnostics stock overvalued right now?
Hemagen Diagnostics (HMGN) has a current Ending Cash Position of $0.07 Mil. The current Ending Cash Position is $0.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Hemagen Diagnostics (HMGN), the current Ending Cash Position is $0.07 Mil as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemagen Diagnostics Business Description

Address 9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.